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AbstrACt
Digital data generated in the course of clinical care are 
increasingly being leveraged for a wide range of secondary 
purposes. Researchers need to develop governance 
policies that can assure the public that their information 
is being used responsibly. Our aim was to develop a 
generalisable model for governance of research emanating 
from health data repositories that will invoke the trust of 
the patients and the healthcare professionals whose data 
are being accessed for health research. We developed our 
governance principles and processes through literature 
review and iterative consultation with key actors in the 
research network including: a data governance working 
group, the lead investigators and patient advisors. We 
then recruited persons to participate in the governing 
and advisory bodies. Our governance process is informed 
by eight principles: (1) transparency; (2) accountability; 
(3) follow rule of law; (4) integrity; (5) participation and 
inclusiveness; (6) impartiality and independence; (7) 
effectiveness, efficiency and responsiveness and (8) 
reflexivity and continuous quality improvement. We 
describe the rationale for these principles, as well as their 
connections to the subsequent policies and procedures we 
developed. We then describe the function of the Research 
Governing Committee, the majority of whom are either 
persons living with diabetes or physicians whose data are 
being used, and the patient and data provider advisory 
groups with whom they consult and communicate. In 
conclusion, we have developed a values-based information 
governance framework and process for Diabetes Action 
Canada that adds value over-and-above existing scientific 
and ethics review processes by adding a strong patient 
perspective and contextual integrity. This model is 
adaptable to other secure data repositories.
bACkground
Digital data generated in the course of clin-
ical care are increasingly being leveraged for 
a wide range of secondary purposes. These 
include health research by both public and 
private sector researchers. Recent events 
involving questionable uses of these records 
have shaken the confidence of the public 
regarding potential misuse of their personal 
information.1 2 As the number and size of 
health information platforms grow, and data 
linkages continue to become more exten-
sive, researchers need to develop governance 
policies that can assure the public that their 
information is being used ethically, securely 
and with a clear public interest. In this 
paper, we present the conceptual and opera-
tional governance frameworks developed for 
Diabetes Action Canada—a pan-Canadian 
research consortium funded by the Canadian 
Institutes of Health Research’s Strategy for 
Patient-Oriented Research (SPOR) Program 
in chronic disease.3 
Diabetes Action Canada’s mandate is to 
improve the lives of Canadians living with 
diabetes and its related complications. It 
facilitates connections between patients, 
their primary healthcare providers, special-
ists and health researchers with the goals of 
improving healthcare and reducing costs to 
the healthcare system. A key component of 
its mandate is to conduct patient-oriented 
research to help achieve these goals.4
To support its research activities, Diabetes 
Action Canada has developed a national 
diabetes repository—a secure analytical 
research environment situated at the Centre 
for Advanced Computing at Queen’s Univer-
sity in Kingston, Ontario—where analyses can 
be conducted securely in a virtual environ-
ment.5 The data in the repository originate 
from the electronic medical records (EMRs) 
from the practices of family physicians who 
strengths and limitations of this study
 ► The governance framework is built on values-based 
principles designed to gain the trust of patients and 
healthcare providers.
 ► Half of the research governing committee members 
are people living with diabetes or their caregivers.
 ► While this is a case study, we believe the govern-
ing principles are generalisable to other health re-
search data repositories, and the operational model 
is adaptable to other settings.
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contribute to the Canadian Primary Care Sentinel Surveil-
lance Network (CPCSSN).6
The CPCSSN extracts de-identified EMRs from 
the practices of consenting primary care providers. 
Structured data from the chart are included as well as 
selected free-text terms. This includes data from the 
summary health profile such as health conditions, aller-
gies and immunisations. CPCSSN also extracts selected 
laboratory data, vital signs, medications prescribed, 
dates of encounters, dates and types of referrals and 
risk factors (smoking status, alcohol use) and patient 
demographics.6
Patients are notified of the collection for research 
purposes through posted notices in the physicians’ 
offices. Patients can opt out at any time by contacting a 
member of the practice-based research network in their 
region. Notices advising patients of this are posted in the 
offices of participating primary care providers.7
The data extracted from these patients’ records are 
de-identified at the source. Prior to de-identification, a 
pseudonymous variable is generated and a key code file 
allowing reidentification is generated at the site of care 
and left there. This permits linkage with other records 
and reidentification of records at source. Only the subset 
of records of persons living with type 1 or type 2 diabetes 
is imported into the repository.
Other systems internationally use similar methods to 
extract, transform and manage primary care EMR data 
for purposes of clinical research, epidemiology and the 
study of health systems. As an example, the UK’s Clinical 
Practice Research Datalink (CPRD) has been in exis-
tence for over 30 years.8 The CPRD extracts de-identified 
data that are similar to those in CPCSSN and manages a 
growing list of research services based on these data. It 
has been part of more than 2000 peer-reviewed publica-
tions on a range of topics including medication use and 
safety, health policy and chronic disease management. 
The CPCSSN has now been in existence for a decade; its 
pattern of growth and development as Canada’s primary 
care EMR repository is following a path similar to the 
CPRD’s.
During this developmental phase, access to the data in 
the repository is restricted to researchers within Diabetes 
Action Canada. In future, the intention is for this to be 
open to outside researchers.
Early on, the need to develop a process to govern access 
to the data was recognised. While there was a consider-
able body of literature addressing information gover-
nance within the business literature, at the outset of this 
project, we were aware of relatively little literature in the 
context of health data repositories.9–13
In this paper, we describe the conceptual and opera-
tional models that were developed for the Diabetes Action 
Canada research governance process, with the hope that 
it may provide a model for other researchers who are also 
addressing similar issues over governance of the research 
in their research network.
Aim
To develop a generalisable model for governance of 
research emanating from health data repositories that 
will invoke the trust of the patients and the healthcare 
professionals whose data are being accessed for health 
research.
methods
Our work was informed by three sources of literature:
1. Basic business texts in data governance.14 15
2. A database of 32 articles gathered from the authors’ 
existing library and recommendations from our data 
governance working group.
3. A scoping review of the literature using Ovid Medline 
from 2000 to 2017, with the assistance of a health sci-
ences research librarian.
The full scoping review process and resulting analysis 
are the subject of a forthcoming publication. Search terms 
for the scoping review combined the topics of biobank and 
EMRs, governance and regulation, and social licence and 
trust. This returned 1075 articles, which were combined 
with the earlier database of 32 articles. On screening of 
abstracts of the 1075 papers, 122 articles were identified 
for coding in NVivo by the two authors. The initial coding 
scheme was developed based on guidance from the busi-
ness texts and input from the data governance working 
group. The coding scheme was amended following the 
initial pilot coding of the first five papers. The results of 
this analysis informed the development of the concep-
tual and operational models for information governance 
models described in this paper.
The draft conceptual model was developed first. This 
was vetted through face-to-face meetings, initially with 
the data governance working group members, which 
included a patient representative. Feedback largely 
consisted of requests for clarification or elaboration on 
the principles selected. After a couple of iterations, the 
draft was then presented to the executive director and 
lead investigators of the network for their feedback, 
and with the general patient advisory circle, which has 
patient representatives from several of the more special-
ised patient advisory circles associated with the network. 
At the executive level and in the patient circle, there was 
strong endorsement, particularly for the participatory 
component being advocated.
The operational framework was developed in conjunc-
tion with both the data governance working group and 
the technical working group that was responsible for 
developing the operational model for the repository. 
The names and affiliations of the data governance and 
technical working group members may be found in 
online supplementary appendix 1. The technical working 
group was fortunate to have a patient representative with 
a strong systems background. The operational framework 
was designed to address the oversight process for requests 
to access the data in the repository, as opposed to the tech-
nical and procedural security aspects. A similar process 
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was used for vetting the operational model as was done 
for the conceptual model. As with the conceptual model, 
revisions consisted more of refining and clarification.
Once the models were endorsed by these groups, we 
recruited patients, healthcare professionals, researchers 
and an individual with content knowledge in research 
ethics to participate in the governing and advisory bodies. 
Patients were recruited through the network partners who 
were responsible for recruiting participants in the patient 
advisory circles. Healthcare professionals were recruited 
through our partners in the Canadian Primary Care 
Sentinel Surveillance System. The two researchers were 
selected from within the network on the basis of their 
expertise in observational and clinical trials research.
In the next section, we describe the relevant literature 
that informed our models, the models we developed and 
the initial operation of the governance process.
results
Conceptual model
Considerations
There are many definitions of information governance. 
We started with Smallwood’s definition: ‘…the overar-
ching polices and processes to optimize and leverage 
information while keeping it secure and meeting legal 
and privacy obligations, in alignment with stated organi-
zational business objectives.’14 From this definition, we 
abstract three core goals of information governance:
1. To optimise data use to meet one’s business objectives.
2. To keep the data secure.
3. To meet legal and privacy obligations.
While this definition works well for private sector data 
holdings and uses, in the context of research using data 
generated in the course of healthcare, additional consid-
erations come into play. In the business model, the busi-
ness entity usually owns the data and leverages the data to 
meet its business objectives. Hence, the individual firm is 
responsible for its information governance policies and 
practices.
In the context of a public sector health research 
network, data are often drawn from multiple parties 
where there is often no clear single owner of the data. 
Indeed, privacy legislation in Canada does not discuss 
ownership of data. It is framed in the language of custody 
and control over data, and to duties and obligations of 
those holding the data. Similarly, in the UK, the revised 
Caldicott principles delineate six principles for the 
secure management of personal health information. 
The updated version added a seventh principle: the duty 
to share information can be as important as the duty to 
protect patient confidentiality.16
Consequently, we suggest that, for health research, it 
is more appropriate to refer to stewardship rather than 
ownership of data. In addition, contributors to the 
research enterprise should carry a collective responsi-
bility for information governance and the business objec-
tive must also meet a public interest test.17
Further, for use of data in the public sector, it is now 
recognised that, to ensure social licence for use of the 
data, the information governance objectives may need 
to go beyond mere compliance with formal regulations.1 
Laurie and Sethi argue that ‘a good governance frame-
work needs to include an overt statement of the values 
and standards according to which activity will be assessed. 
This must be accessible and sufficiently adaptable to 
be adopted and implemented across all levels of deci-
sion-making and by all actors involved in the process.’13 
Similarly, Barocas and Nissenbaum state that ‘procedural 
approaches cannot replace policies based on substantive 
moral and political principles that serve specific contex-
tual goals and values.’18
Based on these considerations, we added a fourth 
objective to Smallwood’s three core goals of information 
governance:
4. Earn and maintain the trust of patients, partners, data 
providers and the public for use of data for research in 
the public interest.
Trust is, in fact, a linchpin in the public acceptability 
of the research enterprise. Carter et al argue that: ‘… 
individuals’ cooperation with speciﬁc research studies 
is usually secured through three principal mechanisms: 
their expectations about how research is conducted and 
regulated; their trust in the institutions and individuals 
who recruit them; and their beliefs in the wholesomeness 
and public value of the research endeavour.’ 1
Elsewhere, they expand on the trust element: ‘the 
public’s support and tolerance for research, and its asso-
ciated risks, often depends far more on an often fragile 
set of cues about the safety and social good of research 
participation, and on institutional and professional 
credentials, than it does on the formal architecture of 
research regulation, or on rational assessment of the 
detail of information sheets or other documents aimed 
at gaining ‘informed consent’.’ That does not negate 
the importance of attention to details around regula-
tion and good communications. It does, however, point 
to the fragile dependence of the research enterprise on 
care taken by all researchers to ensure that their work is 
conducted with high integrity and that the public interest 
in the research is clearly articulated.
Trust assumes some level of uncertainty and, conse-
quently, vulnerability.19 We recognised that much of the 
information use being planned would take us into ‘grey 
zones’ of research use: the indistinct interface between 
research and clinical practice, the healthcare system 
and management of the health of populations of people 
living with diabetes. Consequently, we identified the need 
to incorporate reflexivity into our research governance 
process. That is, the governance process has to critically 
assess common regulatory assumptions and practices in 
the context of new research circumstances and test alter-
native assumptions and practices.20
Particularly when the individual does not have an 
opportunity to exercise control over the use of their data, 
it is important to ensure that the public or patients, as 
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appropriate, be involved at multiple stages in the gover-
nance process. The importance of stakeholder involve-
ment in governance has been widely recognised.21–25
Finally, we needed to consider how the governance 
process we developed would complement the existing 
scientific and ethics review processes to which any research 
protocol would also be subjected. Given the focus on trust 
of both patients and the healthcare professionals whose 
data were being used, we chose to focus on how best to 
account for the patient’s perspective throughout all stages 
of the research process.
Guiding principles
Based on the considerations above, we identified eight 
principles that would guide our governance process:
1. Transparency.
2. Accountability.
3. Follow rule of law.
4. Integrity.
5. Participation and inclusiveness.
6. Impartiality and independence.
7. Effectiveness, efficiency and responsiveness.
8. Reflexivity and continuous quality improvement.
While these principles have drawn from a wide cross-sec-
tion of literature, the model has been particularly influ-
enced by the conceptual work of Laurie and Sethi, who 
called for values based—as opposed to technical—prin-
ciples and the incorporation reflexivity to proceed in 
the face of uncertainty.11–13 26 Smallwood’s definition of 
information governance informed the first three princi-
ples14 and Carter et al, who highlighted the importance of 
public trust and social licence inspired the introduction 
of the integrity principle.1
Below, we provide a brief description of how these 
broad principles inform our operational governance 
process, and how these principles map to the four goals 
of information governance described above. A more 
detailed explanation of the principles may be found in 
online supplementary appendix 2.
Transparency
All decisions, policies and practices regarding data use 
are freely accessible to those affected by the decisions and 
to the public. These shall be available in an easily under-
standable format. (maps to: earn and maintain trust; 
meet privacy obligations)
Accountability
A governing body is accountable to those who will be 
affected by its decisions or actions. This is enforced 
through transparency and the rule of law. (maps to: earn 
and maintain trust, meet legal obligations)
Following the rule of law
The governance framework should follow all appropriate 
legal frameworks and the governing body should ensure 
compliance with applicable laws, regulations, standards 
and organisational policies across jurisdictions and 
institutions. (meet legal obligations, earn and maintain 
public trust)
Integrity
The governing process should ensure that uses of the 
data:
1. Have a clear patient/public interest that is consistent 
with the intended purpose of the repository?
2. Are of high scientific and ethical integrity? Ethical 
integrity includes: respect for persons, beneficence/
non-maleficence and justice. Justice includes concern 
for equity.
3. Are maintained in a secure and private manner? 
(Meet business objectives; meet legal and privacy ob-
ligations; earn and maintain trust; keep data secure).
Participation and inclusiveness
Patients and their families, healthcare professionals, 
and researchers should participate in governance over 
data use—through ongoing communication between 
the research governing committee (RGC) and the three 
patient advisory circles (general, francophone and immi-
grant, and Indigenous), and other stakeholder advisory 
groups.
The governing bodies responsible for access to data in 
the repository should account for differing interests to 
reach a broad consensus on what is in the best interest 
of those with diabetes and their families. Participation 
in governance should be inclusive, equitable, informed 
and organised. The full range of positions of the advisory 
groups should be considered. Ongoing, two-way engage-
ment between the governing body and advisory groups is 
best. (Earn and maintain trust)
Impartiality and independence
As described above, the goal in deliberations is to reach 
a broad consensus on what is in the best interest of those 
living with diabetes and their families. All members in 
the process must look beyond their personal interests as 
either patients, healthcare providers or researchers.
In addition, the governance process must be able 
to operate in a zone of bounded independence27 from 
management, to ensure that its decisions are free from 
institutional conflicts of interest. (Earn and maintain 
trust)
Effectiveness, efficiency and responsiveness
Governance over the data repository should ensure the 
objectives of the organisation are being met in an effec-
tive and efficient fashion. The governing processes should 
serve all within a reasonable time frame. (Earn and main-
tain trust; meet business objectives)
Reflexivity and continuous quality improvement
Information governance should include processes that: 
allow research to proceed in the face of uncertainty; and 
incorporate continuous learning and quality improve-
ment from prior experiences with data use. It should 
promote a culture of reflexivity, and responsiveness 
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among researchers and those governing access to the 
data.26 (Earn and maintain trust).
operational model
Structure
Building on these governance principles, we then formu-
lated an operational model for our governance process. 
In this section and the next, we make explicit links to 
these guiding principles.
Our operational model is summarised in figure 1. 
Below, we focus on the roles of the RGC and its internal 
and external advisory groups.
Research governing committee
The RGC is the overall authority for governance over any 
research—observational studies or clinical trials—that 
are conducted involving data or patients in the network. 
It has decision-making authority regarding individual 
studies. The committee is accountable to the steering 
council, the highest authority in Diabetes Action Canada. 
(Principle 2: accountability; Principle 6: impartiality and 
independence.)
In its early stages, the committee is reviewing all appli-
cations. This will help it work through and document 
the important issues in approving applications and to 
develop standardised approval policies so that, in future 
when volumes increase and processes become routine, it 
will only have to review studies that have been flagged by 
the repository manager as requiring committee input.
There are two ways in which the RGC adds value over 
and above scientific and ethics review. First, it ensures 
contextual integrity of the research, through an intimate 
understanding of the data and the healthcare settings in 
the system being studied. Equally important, it ensures a 
patient-centred perspective of the research, by checking 
that the research:
1. includes patient-relevant outcomes;
2. has taken into adequate account benefits and bur-
dens/risks among people living with diabetes;
3. is engaging in good communication practices with re-
search participants, particularly around approaching 
and consenting to participate in research and in com-
municating about use of their health information for 
research? (Principle 4: integrity of purpose).
Half of the committee members (n=6) are people who 
are living with diabetes or their caregivers. These people 
were identified chiefly through the network partners who 
were responsible for creating the patient advisory circles, 
from the same pool of patients used to recruit the patient 
advisory circle members. Another two members are 
representatives from the data provider advisory group, 
described below. Currently, these are physicians who are 
members of CPCSSN, a subset of whose de-identified 
Figure 1 Diabetes Action Canada research governance structure.
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EMRs reside in Diabetes Action Canada’s secure data 
repository. Another two members are researchers, 
whose roles are to be technical advisors around scientific 
validity and merit of the research proposal. The other 
two members are individuals with expertise in research 
ethics or law. The committee may draw in outside experts 
if required. One of the two co-chairs of the committee is a 
patient representative. The other co-chair is drawn from 
the rest of the members of the committee. (Principle 5: 
participation and inclusiveness).
Data provider advisory group
Currently, the main data source for research activities of 
the network consists of the de-identified EMRs of physi-
cians participating in CPCSSN. The data provider advisory 
group was developed to ensure that the perspectives of 
these data providers are represented at the RGC, through 
two members that group participate on the RGC. Three 
of the seven members of the group are front-line family 
physicians (ie, not academics). Current members were 
suggested by CPCSSN executive. In future, as the sources 
of research data grow, other healthcare professionals and 
data providers will be added to this advisory group.
This group provides advice on research applications, 
considering: logistics of conducting the research in the 
practice setting (particularly if a clinical trial); design 
considerations, as they relate to practice-level decisions 
and interpretation of findings. They also serve as liai-
sons with the larger group of practices that are providing 
data to the repository. (Principle 5: participation and 
inclusiveness).
Patient circles
Patient circles were developed at the outset of Diabetes 
Action Canada.28 Patient circle members either have 
diabetes themselves or are caregivers for a person living 
with diabetes. They are called on individually and collec-
tively for advice on multiple aspects of the network 
endeavours.
Currently, there are three patient circles:
1. The general patient circle (10–15 people).
2. The francophone and immigrant patient circle (6–8 
people).
3. The indigenous patient advisory circle (8–15 people).
Members of the patient advisory circles have been 
drawn from multiple sources, including: an online survey, 
snowball sampling and from community organisations. 
Members are selected to maximise diversity in age, 
gender and geographical location. In addition, candi-
dates are interviewed to identify those with good group 
skills and a desire to contribute to a goal that exceeds his/
her own health situation. They are then offered training 
in patient-oriented research.
The six patient representatives on the RGC have been 
identified from the general patient circle and from a 
list of potential candidates for the circles maintained by 
Diabetes Action Canada. The patient co-chair of the RGC 
provides reports to the general patient circle, apprising 
them of the activity of the RGC and soliciting their input, 
should there be any controversial issues with which they 
are grappling. The general patient circle is the liaison 
point because there is representation from the franco-
phone and immigrant, and the indigenous patient circles 
in the general patient circle. (Principle 5: participation 
and inclusiveness). Further, there will be a separate gover-
nance process developed for research involving indige-
nous people.
External ethics advisory group
This committee will act as a ‘critical friend’ to advise 
on issues that cannot be resolved through deliberations 
among RGC members and the internal advisory groups 
described above. This advisory group provides one more 
instance of the governing principle of reflexivity. It will be 
at arm’s length to the RGC. It carries no formal authority, 
but has the freedom to go public if it is concerned about 
some particular policy direction taken by Diabetes Action 
Canada. Members will be drawn from ethics and legal 
scholars outside Diabetes Action Canada, both nationally 
and internationally, with expertise in: governance over 
secondary use of data; privacy and access to data; regis-
try-based clinical trialsand practice-based research. (Prin-
ciple 8: Reflexivity and continuous quality improvement).
Process
Standard operating procedures, including application 
forms, have been developed. A summary of the appli-
cation process for research use of the data is provided 
in online supplementary appendix 3.
In the application form, several questions focus on the 
patient orientation of the research. For example, the 
researcher is asked to indicate:
A. The patient outcomes being measured.
B. How the research will benefit those living with diabe-
tes or the public more generally.
C. The potential research-related risks of the study to 
research participants/data subjects and potential ad-
verse social implications of the research.
D. The ways in which people living with diabetes have 
been involved in the planning of the research. (Prin-
ciple 4: integrity of purpose, scientific integrity, ethical 
integrity).
The repository manager reviews the application for 
completeness. If the project has not received scientific 
review, the protocol is sent to a scientific advisory group 
for their approval prior to review by the RGC. Researchers 
are encouraged to submit prior to research ethics 
board (REB) approval to ensure the feasibility and appro-
priateness of the proposed protocol from the perspective 
of Diabetes Action Canada. In that way, rework at the 
level of the REB is minimised. (Principle 4: scientific and 
ethical integrity; Principle 7: effectiveness, efficiency and 
responsiveness).
Applications for research use of the data are circulated 
to RGC members at least 2 weeks in advance, to provide an 
opportunity for patient and data provider members of the 
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committee to identify issues requiring deliberation with 
their respective advisory group, in advance of the RGC 
meeting. (Principle 5: participation and inclusiveness).
At the committee meeting, when vetting a partic-
ular protocol, patient and data provider representatives 
are invited to comment first. Concerns raised by the 
researchers and ethics people follow thereafter. The 
committee members aim for a consensus-based resolu-
tion to any concerns. When committee members fail to 
come to consensus, even subsequent to consultation with 
the patient advisory circles and the data provider advisory 
group, The RGC may turn to the ethics advisory group 
for guidance on how to proceed with an application or 
to seek general policy direction. (Principle 5: participa-
tion and inclusiveness; Principle 6: impartiality and inde-
pendence; Principle 8: reflexivity and continuous quality 
improvement).
For applications in which concerns have been raised 
that there is insufficient patient or healthcare provider 
input into the research, the committee may exercise 
the option to assign a patient or healthcare professional 
member of the committee (or one of the advisory groups) 
to become a collaborator on the project to provide advice 
and the patient’s or HCP’s perspective on the research, 
throughout the project. They also retain the option to 
review a draft report prior to publication of findings. 
(Principle 4: scientific integrity (to ensure adequate 
inputs) and Principle 5: participation and inclusiveness).
The repository manager will monitor the time required 
for protocols to pass various checkpoints in the system, 
to identify any unnecessary bottlenecks in the system and 
make recommendations for process improvement. (Prin-
ciple 7: effectiveness, efficiency and responsiveness; Prin-
ciple 8: reflexivity and continuous quality improvement.)
Finally, Diabetes Action Canada is in the process of 
posting:
 ► Its policies around data collection, access, use and 
retention of data.
 ► Its business processes and governance activities; so 
they can be readily accessible to partners and the 
public. In future, it will also perform regular audits of 
its data use practices. (Principle 1: transparency; Prin-
ciple 2: accountability).
Implementation
In January of 2018, a daylong training workshop was 
convened for the RGC. A training manual was produced 
for that purpose, and will be posted on the Diabetes 
Action Canada website. Topics covered in the workshop 
included:
 ► An explanation of the types of studies that they would 
be encountering (data studies; studies making direct 
contact with patients and hybrid studies).
 ► The stages of the research process and how the RGC 
fits into this.
 ► What are research governance and information 
governance and how will they be applied in the context 
of Diabetes Action Canada’s secure data repository?
 ► Diabetes Action Canada’s governing principles, and 
how these may apply when reviewing protocols.
 ► What is the ‘added value’ of the RGC vis-à-vis scientific 
and ethic review.
 ► The structure and function of the governing process 
and their specific contributions.
Participants were then led through two case studies to 
test out the application and review process.
evaluation
At the time of writing, the Diabetes Action Canada secure 
data repository has been available for research for only 
a few months. We are in the early days of implementing 
the governance process and we are still refining those 
processes—both the internal functioning of the RGC 
and the consultative processes. We are also continuing to 
address learning needs of RGC members.
Similarly, our plans for the evaluation of the gover-
nance process are in the formative stages. Drawing from 
relevant SPOR29 and the Patient-Centered Outcomes 
Research Institute (PCORI)30 evaluation frameworks, key 
issues that we will address in the evaluation include:
 ► Outcome measures, such as: the proportion of projects 
reviewed in which changes were recommended and 
the nature of the changes recommended, including: 
(1) addition of more patient-relevant outcomes, (2) 
improvements in participant communications mate-
rials (eg, consent forms and information materials) 
and (3) reductions in risks and burdens to patient 
participants.
 ► Process measures, such as: patient representatives’ 
sense of empowerment in the process; and the time-
liness of the reviews—both objectively and from the 
perspective of researchers who submit applications.
 ► Periodic review of Diabetes Action Canada’s infor-
mation governance processes and procedures on to 
ensure that they conform to and are congruent with 
the objectives and principles enunciated in this paper.
disCussion
In Canada, governance over research involving humans, 
their data, and their samples focuses on the scientific 
and ethical integrity of the research. Scientific integrity 
is largely addressed though peer-review processes at the 
funding and publication stages of the research life-cycle, 
much like research in other jurisdictions. Ethical integrity 
is formally addressed through review of research proto-
cols prior to study commencement by research ethics 
boards at the researchers’ institution(s). Ethics guidance 
is provided by the Tri-Council Policy Statement on Ethical 
Conduct for Research Involving Humans, second edition, 
which addresses research involving human participants, 
their tissue, or their data.31 For database research, one 
still needs to consider relevant privacy laws, which are a 
provincial jurisdiction. These provincial privacy laws have 
provisions for secondary research use of data without 
consent. While they are substantively similar, founded on 
the Canadian version of the Organization for Economic 
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Cooperation and Development (OECD) Privacy Princi-
ples,32 33 there are notable inconsistencies across prov-
inces. Some have health-specific privacy legislation, others 
legislation that covers all sectors; some have multiple 
legislation to consider. In some cases, small differences 
in wording and interpretation of legislation present chal-
lenges to cross-national data studies.
Most legislation also requires the review and approval 
of the research protocol by the institution that is the legal 
data custodian or steward of the data. While Diabetes 
Action Canada does not currently manage personal—
that is, identifiable—health information, the data it 
holds are of sufficient granularity as to make it possible 
to indirectly reidentify individuals, should the data be 
linked or manipulated. Therefore, data in its custody are 
not released to researchers. Instead, the researcher must 
apply for permission to gain secure remote access to the 
data for analyses.
Within this research governance landscape, Diabetes 
Action Canada has developed and implemented an infor-
mation governance process designed to foster public trust 
in the responsible use of the data in their custody. The 
operational model has been designed to complement 
the scientific and ethics review processes that research 
already receives, and is adaptable to other settings.
We believe the principles in the conceptual model we 
developed are generalisable to many other settings. That 
being said, we advise that any organisation that considers 
adopting these principles critically analyse whether they 
are consonant with the values of the organisation, as it is 
these core principles to which they will repeatedly return 
when making difficult or controversial decisions.
While all eight governing principles enunciated are 
important in fostering public trust, the integrity and 
participation principles are particularly relevant. The 
integrity principle establishes the criterion that the 
research must have a clear patient or public interest, and 
be of high scientific and ethical integrity. The participa-
tion principle ensures the substantive participation of 
patients and other relevant stakeholders, which helps to 
achieve the integrity principle.
Over the past decade, there have been many studies 
examining the public’s or patients’ attitudes towards 
the conditions under which data studies may be accept-
able.34 Much less common is the involvement of patients 
or the public in an ongoing fashion in the governance 
over programmes of data-intensive research. The closest 
exemplar we were able to find in the area of data-intensive 
research is the consumer panel for data linkage research, 
associated with the Secure Anonymized Information 
Linkage (SAIL) databank.35 Their panel is advisory in 
nature, addressing both access policy and individual proj-
ects and representatives of that panel sit on an indepen-
dent Information Governance Review Panel.
The governance process developed for Diabetes Action 
Canada goes one step further. It gives people living with 
diabetes and data providers majority representation in 
the key decision-making body in the governance process. 
We are unaware of any other research governance struc-
tures that have instilled as strong a role for patients and 
healthcare professionals in a research network. We are 
not suggesting that all research networks should choose 
as radical a path. However, we believe strong lay participa-
tion in policy-making and governance is an increasingly 
important approach to securing the trust of the public.
As our research platforms grow in size and scope, the 
need for public trust in the uses of these datasets also 
grows. We believe our model for governance over health 
information platforms adds substantively to the concep-
tual and methodological foundations for information 
governance to help address this need.
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